A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.
Bluebird in fundraising mode: A $150M public offering and a deal to get cash early from gene therapy sales
Facing a financial void it had hoped to be filled by a priority review voucher, bluebird bio is tapping two different sources to bring in